Promethos Capital LLC Has $10.69 Million Holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY)

Promethos Capital LLC boosted its holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 402.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 677,184 shares of the company's stock after acquiring an additional 542,450 shares during the quarter. Dr. Reddy's Laboratories comprises about 3.8% of Promethos Capital LLC's investment portfolio, making the stock its 6th biggest holding. Promethos Capital LLC owned 0.08% of Dr. Reddy's Laboratories worth $10,693,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. EverSource Wealth Advisors LLC boosted its stake in shares of Dr. Reddy's Laboratories by 423.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company's stock worth $29,000 after acquiring an additional 1,507 shares in the last quarter. Glass Jacobson Investment Advisors llc boosted its holdings in shares of Dr. Reddy's Laboratories by 400.0% in the fourth quarter. Glass Jacobson Investment Advisors llc now owns 2,000 shares of the company's stock worth $32,000 after buying an additional 1,600 shares during the period. POM Investment Strategies LLC lifted its holdings in shares of Dr. Reddy's Laboratories by 400.0% in the fourth quarter. POM Investment Strategies LLC now owns 2,275 shares of the company's stock valued at $36,000 after purchasing an additional 1,820 shares in the last quarter. Farther Finance Advisors LLC boosted its position in shares of Dr. Reddy's Laboratories by 461.0% in the fourth quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company's stock worth $40,000 after buying an additional 2,093 shares during the period. Finally, Independence Bank of Kentucky grew its holdings in shares of Dr. Reddy's Laboratories by 400.0% during the fourth quarter. Independence Bank of Kentucky now owns 2,775 shares of the company's stock valued at $44,000 after buying an additional 2,220 shares in the last quarter. 3.85% of the stock is owned by institutional investors and hedge funds.

Dr. Reddy's Laboratories Stock Up 1.8 %

NYSE:RDY traded up $0.25 on Friday, hitting $13.69. 2,412,404 shares of the company's stock traded hands, compared to its average volume of 1,439,718. The firm has a 50-day moving average price of $13.16 and a 200-day moving average price of $14.29. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. The company has a market cap of $11.42 billion, a PE ratio of 21.79 and a beta of 0.51. Dr. Reddy's Laboratories Limited has a 1 year low of $12.26 and a 1 year high of $16.89.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last posted its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. Equities analysts anticipate that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current fiscal year.

Dr. Reddy's Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.